Inductive Bio Raises $25M Series A to Transform Small Molecule Drug Discovery with Industry-Wide AI Platform

Inductive Bio完成2500万美元A轮融资，利用行业广泛的人工智能平台变革小分子药物发现

Funding will accelerate company's work to democratize state-of-the-art AI models trained on a pre-competitive dataset to speed the successful development of life-saving therapies

资金将加速公司的工作，使最先进的AI模型训练在竞争前的数据集上实现民主化，以加快挽救生命疗法的成功开发。

NEW YORK, May 7, 2025-- Inductive Bio, a technology company democratizing artificial intelligence (AI) models to transform small molecule drug discovery, announced today that it has raised $25M in Series A financing led by Obvious Ventures with participation from Andreessen Horowitz (a16z) Bio + Health, Lux Capital, S32, Character, and Amino Collective, alongside angel investors including Oren Etzioni, Jeff Hammerbacher, Malay Gandhi, and Jakob Uszkoreit..

纽约，2025年5月7日——Inductive Bio是一家技术公司，致力于将人工智能（AI）模型普及化以变革小分子药物发现，该公司今天宣布已完成由Obvious Ventures领投的2500万美元A轮融资。Andreessen Horowitz（a16z）Bio + Health、Lux Capital、S32、Character和Amino Collective参与了本轮融资，同时还有包括Oren Etzioni、Jeff Hammerbacher、Malay Gandhi和Jakob Uszkoreit在内的天使投资人。

The funding comes at an inflection point for the pharmaceutical industry, which faces pressure on multiple fronts: increasingly scarce early-stage funding, growing competition from Chinese biotech companies, and a traditional drug discovery process that remains inefficient and expensive. One of the biggest bottlenecks in the preclinical drug discovery process is the enormous amount of time and money needed to balance a drug's potency with the critical properties of absorption, distribution, metabolism, excretion, and toxicity (ADMET)..

这笔资金正值制药行业的转折点，该行业在多个方面面临压力：早期融资日益稀缺，来自中国生物技术公司的竞争日益激烈，传统的药物发现过程仍然效率低下且昂贵。临床前药物发现过程中最大的瓶颈之一是需要耗费大量时间和金钱来平衡药物的效力与吸收、分布、代谢、排泄和毒性（ADMET）等关键特性。

Inductive's approach centers around its pre-competitive data consortium, where multiple companies contribute anonymized data in a secure IP-protected environment, creating a foundational dataset that allows AI models to learn from thousands of real-world drug discovery programs. The resulting insights power Inductive's Compass platform, which predicts a drug's ADMET properties before a molecule is synthesized — guiding chemists towards molecules with the highest likelihood of success..

Inductive的方法围绕其竞争前数据联盟展开，多家公司在安全的知识产权保护环境中贡献匿名数据，创建一个基础数据集，使人工智能模型能够从数千个真实世界的药物发现项目中学习。由此产生的洞察力为Inductive的Compass平台提供了支持，该平台能够在分子合成之前预测药物的ADMET属性，引导化学家走向成功可能性最高的分子。

'Designing compounds with optimal ADMET properties is a fundamental challenge in drug discovery. This is where predictive AI tools can have a real impact,' said Brock Shireman, SVP of small molecule drug discovery at Rapport Therapeutics. 'By accurately predicting ADMET properties in real time, Inductive's platform helps our chemistry team design higher-quality compounds before investing resources in complex synthesis.'.

“设计具有最佳ADMET特性的化合物是药物发现中的一个基本挑战。这正是预测性AI工具可以产生真正影响的地方，”Rapport Therapeutics小分子药物发现高级副总裁布罗克·希尔曼表示。“通过实时准确预测ADMET特性，Inductive的平台帮助我们的化学团队在投入资源进行复杂合成之前设计出更高质量的化合物。”

Since its launch a year ago, Inductive's Compass software has rapidly scaled to support dozens of active small-molecule drug programs across diverse therapeutic areas. Medicinal chemists have already explored over 1 million molecule designs in the platform. In a recent collaboration with Nested Therapeutics, published in ACS Medicinal Chemistry Letters, Inductive's platform helped efficiently resolve permeability and metabolic stability issues, contributing to the nomination of a drug development candidate with excellent cell potency and cross-species pharmacokinetics..

自从一年前推出以来，Inductive公司的Compass软件迅速扩展，已经支持了数十个活跃的小分子药物项目，涵盖多个治疗领域。药物化学家已经在该平台上探索了超过100万种分子设计。在最近与Nested Therapeutics的合作中（研究成果发表于《ACS Medicinal Chemistry Letters》），Inductive的平台帮助有效解决了渗透性和代谢稳定性问题，助力提名了一种具有良好细胞效力和跨物种药代动力学的药物开发候选物。

Today's funding announcement comes on the heels of the company's first-place finish in the inaugural Polaris ADMET competition, which evaluated AI models in a blinded, open challenge using a recently disclosed Coronavirus Main Protease drug program. Inductive's Beacon-1 model placed top among 38 other competitors from leading AI drug discovery companies and academic groups..

今天宣布的融资消息紧随该公司在首届北极星ADMET竞赛中获得第一名之后，该竞赛使用最近披露的冠状病毒主蛋白酶药物计划，在一项盲测、公开挑战中评估了AI模型。Inductive公司的Beacon-1模型在来自领先AI药物发现公司和学术团体的38个竞争对手中名列前茅。

'In a tough funding environment and an increasingly competitive market, the rapid discovery of high-quality clinical candidates has never been more important for biopharma companies,' said Josh Haimson, co-founder and CEO of Inductive Bio. 'Traditional approaches for optimizing drug molecules are like playing a complex game of 'whack-a-mole' with dramatic consequences for the success or failure of a therapeutic program.

“在资金环境紧张且市场竞争日益激烈的情况下，快速发现高质量的临床候选药物对生物制药公司来说从未如此重要，”Inductive Bio的联合创始人兼首席执行官Josh Haimson说道。“优化药物分子的传统方法就像在玩一场复杂的‘打地鼠’游戏，对治疗项目的成功与否有着巨大的影响。”

Our platform's pre-competitive consortium allows the entire industry to benefit from the rapid advances being made in AI, dramatically accelerating the path to life-changing therapies that will benefit patients for centuries to come.'.

我们平台的预竞争联盟使整个行业能够从人工智能的快速发展中受益，极大地加速了通往改变生命的疗法的道路，这些疗法将使患者受益数百年。

Inductive will use the funding to expand its AI model R&D, grow its pre-competitive data consortium and deploy its technology industry-wide, leveling the playing field for both innovative startups and large pharmaceutical companies. Longer-term, Inductive aims to launch an AI-native contract research organization (CRO) on top of this technology..

Inductive 将利用这笔资金扩大其人工智能模型的研发，扩展其竞争前数据联盟，并在全行业部署其技术，为创新初创公司和大型制药公司创造公平的竞争环境。长期来看，Inductive 旨在基于这项技术推出一家原生人工智能合同研究组织 (CRO)。

'What impressed us about Inductive is that they've moved beyond the hype of AI in drug discovery to deliver measurable results that are already changing how drugs are developed,' said Rohan Ganesh, Partner at Obvious Ventures. 'At Obvious, we believe AI is ushering in a new scientific method, accelerating innovation across fields like biotechnology and healthcare.

“让我们对Inductive印象深刻的是，他们已经超越了人工智能在药物发现领域的炒作，取得了可衡量的成果，这些成果已经在改变药物的开发方式，”Obvious Ventures合伙人Rohan Ganesh表示。“在Obvious，我们相信人工智能正在引领一种新的科学方法，加速生物技术和医疗保健等领域的创新。”

Inductive embodies this shift, showing how these approaches can drive real-world breakthroughs that have the potential to fundamentally transform the economics and pace of drug development.'.

归纳法体现了这一转变，展示了这些方法如何推动具有现实意义的突破，这些突破有潜力从根本上改变药物开发的经济性与速度。

About Inductive Bio

关于感应生物

Inductive Bio has developed a collaborative AI platform that dramatically accelerates compound optimization, a critical and time-consuming step in developing new therapeutics. By building a pre-competitive data consortium and state-of-the-art ML models designed to map the drivers of small molecule Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET), Inductive's platform allows scientists to optimize initial compounds into leads and development candidates faster and with a better balance of ADMET properties..

Inductive Bio 开发了一个协作式 AI 平台，可显著加速化合物优化，这是开发新疗法过程中一个关键且耗时的步骤。通过构建一个非竞争性数据联盟，并利用最先进的机器学习模型来绘制小分子吸收、分布、代谢、排泄和毒性（ADMET）驱动因素的地图，Inductive 的平台使科学家能够更快地将初始化合物优化为先导化合物和开发候选药物，同时实现更优的 ADMET 特性平衡。